Science topics: GynaecologyScreening
Science topic

Screening - Science topic

Screening, in medicine, is a strategy used in a population to detect a disease in individuals without signs or symptoms of that disease. Unlike what generally happens in medicine, screening tests are performed on persons without any clinical sign of disease.
Questions related to Screening
  • asked a question related to Screening
Question
1 answer
please help......I need this infromation ASAP
Relevant answer
Answer
Here are some notable advancements along with their pros and cons:
1. Dual-Energy X-ray Absorptiometry (DXA):
- Pros: DXA is considered the gold standard for measuring bone mineral density (BMD) and diagnosing osteoporosis. It is widely available, relatively low-cost, and exposes patients to low radiation doses.
- Cons: DXA primarily measures BMD and may not fully capture bone quality and fracture risk. It also has limitations in distinguishing between trabecular and cortical bone.
2. Quantitative Computed Tomography (QCT):
- Pros: QCT provides volumetric BMD measurements and can differentiate between trabecular and cortical bone. It is useful for assessing bone strength and fracture risk prediction.
- Cons: QCT involves higher radiation doses compared to DXA. It is less widely available and more expensive. Additionally, QCT scans may have lower spatial resolution compared to DXA.
3. High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT):
- Pros: HR-pQCT provides detailed three-dimensional imaging of bone microarchitecture. It allows for assessment of trabecular and cortical bone compartments, and evaluation of bone strength and fracture risk.
- Cons: HR-pQCT is limited to peripheral skeletal sites (e.g., wrist or ankle) and is not suitable for central skeletal assessment. It is relatively expensive and less accessible than DXA.
4. Trabecular Bone Score (TBS):
- Pros: TBS is a texture analysis technique applied to DXA scans that provides information about bone microarchitecture. It complements BMD measurements in assessing fracture risk.
- Cons: TBS is an indirect measure of bone microarchitecture and relies on DXA scans. It may not be as informative in certain clinical conditions or when DXA scans are of low quality.
5. Biochemical Markers of Bone Turnover:
- Pros: Measurement of bone turnover markers (e.g., serum levels of osteocalcin or CTX) can provide insights into bone metabolism and response to treatment. They are useful for monitoring bone health and treatment efficacy.
- Cons: Bone turnover markers are influenced by various factors and may not provide a direct assessment of bone strength or fracture risk. Their clinical utility is more limited compared to imaging-based techniques.
Hope it helps: credit AI
  • asked a question related to Screening
Question
2 answers
Dear colleagues,
A research team is conducting a study to evaluate emotions that have been automatically generated by using GANS, through a small survey. The survey presents 20 works of art in four different versions, each aimed at evoking one of the following emotions: amusement, delight, dread, and melancholy.
Your opinion is highly valued. Kindly access the form provided via the link and indicate the emotion you perceive each one of the 20 works of art to evoke. We suggest increasing the screen brightness to have a better view of the images.
Thank you for participating in this research. Your responses will be greatly appreciated. Feel free to share with your contacts.
Relevant answer
Answer
I'm not sure, as we will need to analyse the data and write the paper over the next year.
  • asked a question related to Screening
Question
1 answer
How to use SISSO (Sure Independence Screening and Sparsifying Operator) by PYTHON?Are there any related tutorials or materials?
Relevant answer
Answer
Hi, you have some samples in this project library : https://github.com/Matgenix/pysisso. Author provides some tutorial on a specific file describe on his readme.
  • asked a question related to Screening
Question
2 answers
I am trying to find any research related to mass health screening of general populations anywhere around the world.
Relevant answer
Answer
Probably the largest screening programmes worldwide are the cervical cancer screening programmes. There is a wealth of information about the screening programmes and I would start with national programmes such as the UK Cervical Cancer Screening Programme:
as this has a variety of information on the programme and how it works as well as links to recommendations and the research which backs it up. There are also links to the National Screening Committee which makes the recommendations and through that archives of all the research and reports that show how the programme works. Ireland has a similar, if slightly younger, programme which is probably worth a look too, on the basis of your location, and has worked closely with the UK in its development.
There is a wealth of data on cervical screening and it is one of the oldest programmes going and has a screening population of many millions in a country like the UK with a universal healthcare system.
Hope this helps.
  • asked a question related to Screening
Question
1 answer
Protocol for Screening Low-Density Polyethylene (LDPE)–Degrading Soil Fungi Isolated from Urban Waste Dumping Sites | SpringerLink
Relevant answer
  • asked a question related to Screening
Question
2 answers
When aligning the objective aperture on a F30 in diffraction mode, does the electron beam need to be in the center of the screen? For example look at the picture I have shared. The beam is off centered wen in diffraction mode. Do I need to put the beam in the middle or is it okay if it's not?
Relevant answer
Answer
Var St. Jeor Thank you. Just to clarify, the microscope that I am using is the FEI Tecnai G2 F30 Field Emission Gun Transmission Electron Microscope
  • asked a question related to Screening
Question
5 answers
Is there different solutions and new technologies or research on how we can help on this matter.
Relevant answer
Answer
In developed countries, a variety of safety measures ensures a low risk of transfusion-transmitted infections. These safety measures include donor selection (limiting imported and window infections); skin disinfection and diversion bags (limiting bacterial contamination during blood donation); the screening of donations (enabling timely detection of HBV, HCV, HIV, and Treponema pallidum); specific processing (such as leukodepletion, pathogen reduction, and inactivation, which remove or kill certain pathogens); quarantine plasma (preventing window infections); bacterial culturing (detecting contaminated platelets); and post-donation and post-transfusion notification (respectively, enabling donor- and recipient-triggered look-back procedures, which identify infected recipients).
  • asked a question related to Screening
Question
2 answers
I have a highly conserved pocket in my enzyme that currently has no known function. I'm interested to see whether it binds a particular molecule. I'm wondering if anyone knows of an AI or software that can screen the pocket and identify molecules that are likely to bind there.
Thanks!
Relevant answer
Answer
Please check this "Protein-protein binding site identification by enumerating the configurations"
which may help you.
  • asked a question related to Screening
Question
1 answer
Hello researchers,
I am a student at the SOMT, university of Physical Therapy(The Netherlands) and I am studying for a master degree in Geriatric Physical therapy.
Currently I am working on a school assignment where I want to look further in differentiating sarcopenia (screening) in a nursing home. In a lot of literature I found that the Ishii screening tool is highly
recommended to use. Unfortunately I can't find this tool? This is maybe a bold question but can you maybe help me by telling me where I can find this exact tool?
It would really help me with my assignment :)
Thank you- anyway and also thank you for all your research and very interesting studies.
Relevant answer
Answer
Hi,
You can find it on the following link :)
Hope that helps!
Best of luck from India!
  • asked a question related to Screening
Question
1 answer
Is it more acceptable or tolerable of false positive or false negative in suicide screening for a suicide screening tool?
Relevant answer
Answer
I think goo more tolerate false positive than tolerating false negatives. Tolerating false negative could be dangerous.
  • asked a question related to Screening
Question
7 answers
UNKNOWN DRUGS AND METABOLITES SCREENING USING LCMS
FROM SUSPECTED SAMPLES
Relevant answer
Answer
First establish a method (HPLC, then LC-MS) which follows good fundamentals for a series of expected known drugs and metabolites. *You can not develop a method for "unknowns".
  • asked a question related to Screening
Question
3 answers
I want to develop an understanding for conducting Meta-Analysis studies in Psychology. how many studies to select, how to screen them, any tools which are used for the purpose. kindly explain with references how to conduct a meta-analysis
Relevant answer
Answer
You need to develop a PICOS, then develop a comprehensive search string according to the PICOS, search databases, and screening articles as per the inclusion and exclusion criteria. perform data extraction, analysis, and evidence synthesis. manuscript writing.
It is a long process. I think one should learn before embarking on starting a new project.
  • asked a question related to Screening
Question
5 answers
I need a set of images of emotional faces (angry or sad; neutral; happy) of infants. I would like to frontally present these faces on a screen in a computer experiment. If infant images were matched in size, luminance, position, etc, with other images of adults, it would be great! Yhank you
Relevant answer
Answer
Hi, I do realise this is an incredibly late reply but if you are still looking for resources, I have used the CAFE database.
LoBue, V. & Thrasher, C. (2015). The Child Affective Facial Expression (CAFE) Set: Validity and Reliability from Untrained Adults. Frontiers in Emotion Science, 5.
  • asked a question related to Screening
Question
1 answer
My lab has the NEB Gibson Assembly kit (unfortunately not the Hifi kit) and I have been struggling for months to assemble various different constructs. I'm wondering if anyone has used this kit specifically and if there are any specific things/tricks you do or use?
I have tried to insert 3 fragments (ranging between 500 bp - 2 kb) into a vector backbone, as well as overlap PCRs to insert 1 fragment into the vector. All fragments have between 30-40 bp homology regions. I PCR amplify all of my pieces (including backbone) and gel extract them because we don't have DpnI. I can get the overlap PCR working well, so I thought the primers/homology regions were designed ok. Yet, I can't get a simple 1 insert into 1 vector reaction working - I consistently get zero colonies (occasionally I've gotten an absurdly low number like 2 or 4, but screening them they're false positives).
I've used NEB's positive control to make sure the Gibson mix is working and got many colonies, but unfortunately they don't provide much information on the contents other than it's 2 DNA fragments so I'm not sure how they designed the two fragments to be ligated.
I have typically been adding 50 ng vector and tried both equimolar amounts of insert and 2-3 fold molar excess of insert. Is there a concern that there is too much salt contamination carried over from the gel extraction? I was curious about the positive control NEB provides and nanodrop read quite comparable A260:A230 ratio between that and my fragment mix. I've also tried adding 5% DMSO into the reaction in case secondary structures were preventing efficient assembly, as well as transforming 50 uL of NEB10b with 2uL vs. 10uL of the Gibson reaction. And nothing seems to stick.
Sidenote I tried IVA once and didn't work for me, but if you have any specific recommendations with that I'd also be willing to try troubleshoot that method if I continue to have issues with Gibson.
Relevant answer
Answer
This is a terrible kit, the hi-fi builder is much better at the job. Gibson kit requires more than 6 hrs or even overnight to get the proper assembly done while cloning multiple fragments. Since you are getting assembly products using the overlap extension PCR you can do some things:
1) amplify the fused overlap PCR product using 5' phosphorylated primers/or phosphorylate them after PCR using T4 PNK and then use it for blunt end cloning.
2) try to amplify the vector and. fused product with homology to each other and gel purify/Dpn1 treat them and then directly transform in dh5a, the e coli joins the homology ends in a recA independent homologous recombination reaction within. (One of the easiest and fastest cloning methods I have used to date.)
  • asked a question related to Screening
Question
1 answer
According to an article entitled "Blood Transfusion Safety, current status and challenges in Nigeria" (2017), achieving blood transfusion safety in Nigeria (and likely the rest of Sub-Saharan Africa) remains a difficult task due to a number of factors, including a lack of blood, inadequate implementation of blood transfusion guidelines, insufficient infrastructure, and a high prevalence of transfusion-transmissible infections (TTIs), particularly hepatitis and human immunization. Even though there has been a slight improvement, particularly in the area of screening donor blood for common TTIs, significant efforts are still required in the form of effective public education campaigns (on blood donation) and ongoing system improvement to move the nation's current transfusion practices in the direction of safety and self-sustenance.
Source: Aneke JC, Okocha CE. Blood transfusion safety; current status and challenges in Nigeria. Asian J Transfus Sci. 2017 Jan-Jun;11(1):1-5. doi: 10.4103/0973-6247.200781. PMID: 28316432; PMCID: PMC5345273
Relevant answer
Answer
The following procedures must be followed when handling serum in order to guarantee the highest level of safety for blood transfusions:
A. Donor and recipient ABO and D groupings
- Both the donor and the recipient should have this determined precisely.
B. Extended donor and recipient red cell phenotyping
- In addition to ABO and D antigens, appropriate anti-sera are used to identify other antigens that can lead to immunological sensitizations and reactions, such as: C, E, c, e, K, k, etc.
C. Receipt serum antibody detection and screening
- Standard cell panels should include group O red cells that have been carefully phenotyped and contain all of the antigens that are known to cause transfusion reactions in the area, including D, C, E, C, E, K, K, etc. Additionally, the panels need to contain both homozygous and heterozygous cells for the phenotyped antigens. To demonstrate the dose impact during the antibody identification method, this is required.
Reference:
Ahmed, S. G. (2022). Transfusion services in tropical Africa: Challenges and prospects from the Nigerian perspective. Niger J Haematol, 3, 1-17.
  • asked a question related to Screening
Question
1 answer
Given the disproportionately high risk provided by blood-borne pathogens, regular monitoring of blood transfusions is required to avoid disease transmission. ELISA and Rapid diagnostic immunochromatographic technique are the two most extensively used methods for detecting HBV, HCV, and HIV infection in blood donors. Although ELISA are considered more accurate worldwide. With this, what are the drawbacks of using the rapid immunochromatographic kits for screening blood donors compared to ELISA?
Source: Al-Matary, A. M., & Al Gashaa, F. A. S. (2022, November). Comparison of different rapid screening tests and Elisa for HBV, HCV, and HIV among healthy blood donors and recipients at Jibla University Hospital yemen. Journal of medicine and life. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762378/#:~:text=This%20study%20showed%20a%20significant,infectious%20markers%20for%20blood%20donors.
Relevant answer
The use of rapid diagnostic immunochromatographic technique (ICT) methods are prevalent in developing countries, while ELISA and molecular testing are recognized as more widely accepted for their enhanced accuracy. Rapid diagnostic tests for viral infections have been available since the 1990s, primarily designed for emergency diagnostics, home-based testing, and field surveys. Furthermore, in several deprived regions, rapid diagnostic tests are used as a means to identify infections caused by the hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). This method serves as a solution to address the scarcity of financial resources and medical equipment. Nevertheless, a significant issue regarding the utilization of rapid screening tests revolves around the necessity for these tests to demonstrate an acceptable level of sensitivity and a sufficient level of specificity to reduce the occurrence of false results.
Reference: Al-Matary, A. M., & Al Gashaa, F. A. S. (2022). Comparison of different rapid screening tests and Elisa for HBV, HCV, and HIV among healthy blood donors and recipients at Jibla University Hospital Yemen. Journal of Medicine and Life. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762378/
  • asked a question related to Screening
Question
1 answer
In responding to a request for a text I've always clicked on "View Request" and then get a screen where I can choose to respond or not. I don't get that anymore -- it's just an abstract of the paper they've requested. I can find no way to send the text. Please advise. Thanks.
Relevant answer
Answer
I remember that several users had problems with this at the time you asked. Has the problem been fixed meanwhile?
  • asked a question related to Screening
Question
2 answers
I have try to establish a CRISPR screen in primary T cells,sgRNA transduce with
lentivirus and Cas9 protein delivered by electroporation (SLICE). But in the pilot experiment, we found that the efficiency of knocking out CD45 through this system is very low. The same experiment on Jurkat also failed.
Then I tried to change the experimental conditions, for example, increasing the amount of Cas9 protein or using Cas9 mRNA, or change CD45 sgRNAs.
None of these attempts have improved CD45 knockout efficiency.
I would appreciate it if you could give me some good advice!
Relevant answer
Answer
Thanks for your advice!
Because our library is a single sgRNA in lentiGuide-puro plasmid, so we just try the same backbone with a single CD45 sgRNA, but if there is a library containing 2 sgRNA per plasmid, we could try it.
For your second advice, in fact, before proceeding with electroporation Cas9 protein, we performed a drug screening with puromycin.
Thanks again for your valuable comments and look forward to your reply!
  • asked a question related to Screening
Question
4 answers
Oral cancer has a high morbidity and mortality rate and clinical examination has resulted in late diagnosis. What reason has led to a delay in the implementation of a complementary screening test to the conventional clinical test?
Relevant answer
Answer
Dear Malcolm Nobre I really appreciate every response lead and I'm sorry not to lead a debate so as not to influence new responses. Biomarkers are very interesting, really, but would they allow us to say where the cancer actually is in a molecular stage, let's say (on the tongue? on the soft palate? on the floor?) and how to identify the real location at a stage that biomarkers theoretically allow to identify , at the molecular level or would we have to know that we have a probability of oral cancer and then wait for clinical evidence later to locate the tumor? . Westra explains this issue well. Do other methods in other areas really have great sensitivity or specificity or would it be the approach that facilitates, for example, being able to remove the entire tissue where, in the mouth, we do not have such an approach to remove the entire oral cavity.I really appreciate every direct response about oral cancer screening. who knows, one more question: could it be that many studies no longer confuse screening with diagnosis and brilliant works are lost by a mere confusion of basic concepts? very grateful
  • asked a question related to Screening
Question
1 answer
covidence a screening software, and for full text screening if i want to keep article for my supporting document but not include in study how should i flag it?
Relevant answer
Answer
for such problems, it's important to contact the covidence support team for assistance.
  • asked a question related to Screening
Question
3 answers
Some papers refer to calculate FRAP value as
FRAP value = = [(A1 − A0)/(Ac − A0)] × 2, where Ac is the absorbance of the positive control, A1 is the absorbance of the sample, and A0 is the absorbance of the blank.
Some other papers refer to calculate FRAP value as
FRAP value will be Trolox equivalent using Y=mx+c equation.
Please let me know the original process for the FRAP value calculation.
Relevant answer
Answer
I have conducted the second method in my research. You may refer to my paper
  • asked a question related to Screening
Question
1 answer
Hello, everyone!
I am looking for a dataset where people recorded the simplest possible reaction time task. Something like pressing a button as soon as the screen turns red. Or maybe any variations that are not too far from such an experiment.
I know research on reaction time has been going on for the past ~40 years. But somehow I can not find a dataset for it. Wonder if any of you have seen it?
Thank you in advance!
Vitalii.
Relevant answer
Answer
I'd be emailing the corresponding author of whichever paper describes the sort of dataset that's most relevant to you - for example, someone who has published on "intention to move" vs. muscular response time.
Many journals nowadays require that data be made available upon reasonable request, and I'm sure there are many researchers out there who'd be happy to help you?
  • asked a question related to Screening
Question
5 answers
I am trying to do a impact analysis through workbench explicit dynamics.
I establish the model in Explicit Dynamics and mesh it at first, and then, I go back to the project schematic page and drag the Autodyn component into there. Then, I connect Autodyn and Explicit Dynamics two parts together. I click the " setup" icon in Autodyn part and update it. Later, I go into the screen of Autodyn and find nothing in there. I attach all of my processes in this poster. Is there any body could tell me how to import the model in Explicit Dynamics in Autodyn?
Thank you.
Relevant answer
Answer
You can import your model through any solver in workbench to AUTODYN following the attached video.
  • asked a question related to Screening
Question
4 answers
I need to screen the toxicity of several compounds that will be applied locally to an open wound of bone and muscle injury, which human cell lines (good for several passages) would be most appropriate for this experiment beside hMSC?
Thanks
Relevant answer
Answer
for high throughput screening, how about "Establishing cell line" using bone marrow-derived mesenchymal stem cells since they possess both myogenic and osteoblast potential?
  • asked a question related to Screening
Question
5 answers
I have already used the Capture SELEX method for the screen of small molecules.
Relevant answer
Answer
Aptamers have a wide range of targets, and the size and solubility of the targets are different. Therefore, the application of SELEX technology to screen nucleic acid aptamers can adopt different specific operation methods. Centrifugal precipitation is often used for aptamer screening of cells, bacteria and viruses, and solid-phase adsorption and elution technology can be used for aptamer screening of soluble small molecules. Specific methods for aptamer screening include the following aspects.
Screening methods based on different fixation media. Nitrocellulose membrane filtration is a commonly used method for protein aptamer screening.
Joshi et al. designed a lateral flow chromatographic device based on nitrocellulose membrane. Combining the device with SELEX screening technology, the authors obtained a high concentration of the outer membrane protein (Omp) of Salmonella typhimurium after 7 rounds of positive screening and 3 rounds of reverse screening. Affinity aptamer 33 and 45 sequences with a detection limit of 10-40 cfu/mL. Gel column is also a common immobilization medium for aptamer screening.
Tang et al. used SELEX technology to screen aptamers with high specificity and high affinity for red bean toxin based on agarose gel resin, and their dissociation constants were as low as several nmol. In recent years, the use of microwell plates as immobilization media to screen aptamers has been widely used. Wang Lifeng et al. screened and obtained a high-affinity aptamer sequence that can specifically bind to carcinoembryonic antigen (CEA) based on microwell plate technology. Studies have shown that this aptamer plays an important role in the early diagnosis, monitoring and treatment of tumors.
Fluorescent magnetic beads SELEX (FluMag-SELEX) technology. FluMag-SELEX is a method for screening fluorescent aptamers by combining the application of magnetic beads and SELEX technology. This method requires a small amount of targets and can directly measure the amount of binding ligands through fluorescence. Kim et al. applied FluMag-SELEX technology to screen five specific aptamers of ibuprofen, a broad-spectrum anti-inflammatory drug. Three of them are specific aptamers for racemic ibuprofen, and the other two can specifically interact with racemic and meso ibuprofen. The ibuprofen aptamer has strong specificity and has no binding effect with ibuprofen analogues and oxytetracycline. Xu et al. used FluMag-SELEX technology to screen specific aptamers for PCBs, with dissociation constants at the micromolar level and good linearity in the range of 0.1 to 100 ng/mL.
Capillary Electrophoresis SELEX Technology (CE-SELEX). There is a certain difference in the charge-to-mass ratio between different components, resulting in a difference in the electrophoretic mobility of the substance, thereby achieving the separation of different components. CE-SELEX can realize the screening of high-affinity aptamers within 2-4 rounds, and is often used to screen macromolecular substances such as proteins, lipopolysaccharides, and polypeptides. For the first time, Yang et al. used CE-SELEX to screen the aptamers of the small molecule substance methylmorpholine. After three rounds of screening, eight high-affinity aptamers were obtained, with dissociation constants ranging from several hundred nM to several uM, two of the sequences can catalyze the metal insertion reaction of mesoporphyrin, and the catalytic strength is 1.7 times and 2 times, respectively. Aiming at the problem of dynamic dissociation equilibrium between aptamers with weaker affinity and target systems, researchers have developed non-equilibrium capillary electrophoresis (NECEEM) of equilibrium mixtures, equilibrium capillary electrophoresis of equilibrium mixtures (ECEEM) and Non-SELEX capillary electrophoresis Electrophoresis technology.
Ashley et al. used Non-SELEX technology to screen the aptamers of catalase. The authors characterized their affinity and specificity by using a fluorescence spectrometer and capillary affinity electrophoresis. The affinity of the protein is as high as 100 times, which also shows its high specificity. The aptamer can be applied to biosensor, immunoblotting and biomarker identification. Ashley et al. screened the aptamers of human leptin protein in a free three-dimensional space environment based on NECEEM and SELEX technology, and its dissociation constant was several hundred nM.
Cell SELEX (Cell-SELEX) technology. The main target substances of this method are cells, bacteria or viruses, etc. During the operation, centrifugation and precipitation methods are used to separate and remove unbound suitable ligands, and then specific aptamer sequences are obtained through thermal dissociation or enzyme digestion.
Liang et al. used Cell-SELEX to obtain 5 DNA aptamers after 35 rounds of repeated screening for living cells infected with rabies virus. Virus titer determination and real-time quantitative reverse transcription PCR experiments showed that the five aptamers screened could inhibit the replication of rabies virus, which provided a possibility for the treatment of rabies infection.
Ninomiya et al. used Cell-SELEX to obtain 12 high-affinity aptamers that specifically bind to human liver cancer cell HepG2 after 11 rounds of repeated screening, with dissociation constants ranging from 19-450 nM. The author analyzed and obtained the secondary structure shared by 12 aptamers, which is closely related to the recognition of HepG2. This method can be screened when the nature of the target is unclear and the binding site is not determined, and it does not require a complicated process for preparing the target.tamer screening of cells, bacteria and viruses, and solid-phase adsorption and elution technology can be used for aptamer screening of soluble small molecules.
  • asked a question related to Screening
Question
1 answer
I want to screen for antimicrobial activities of spices extract against fungal isolates from food. what method /methods is best for it?
Relevant answer
Answer
There are plenty of relevant articles on Google Scholar - e.g. https://academicjournals.org/journal/AJMR/article-full-text-pdf/15879FE11467.pdf
  • asked a question related to Screening
Question
5 answers
For example QTL (x) is identified for disease screening in the mapping population where the parents are A and B. Can this QTL (x) be used as marker to screen the another population where its parents are C and D for the disease resistance?
Relevant answer
Answer
Keep in mind that a QTL is detected specifically when the offspring are segregating for different alleles of a gene affecting the trait. E.g. if parents A and B are fixed for functionally different alleles, their F2 offspring will segregate for AA, AB and BB combinations of alleles at a QTL with different degrees of disease resistance. When you cross parents C and D, of both parents are homozygous for a resistance allele or if both are lacking a resistance allele, there will be no QTL effect.
  • asked a question related to Screening
Question
2 answers
E coli strain JM109(DE3) has its genotype listed as endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ Δ(lac-proAB) e14- [F' traD36 proAB+ lacIq lacZΔM15] hsdR17(rK-mK+) (λDE3).
It seems like it should be suitable for blue-white screening because of the lacZΔM15 deletion and but Promega states it isn't suitable. Another supplier, IntactGenomics says it is good for blue-white screening.
Anyone have an explanation? Is it just that it's an expression strain and not a cloning strain?
Thanks!
Relevant answer
Answer
I agree with Robert Adolf Brinzer that JM109 is (in theory) suitable for blue white screening. I have used the non-DE3 version often in the past. However it can lose the F' which carries the lacIq lacZΔM15 fairly easily so you may wish to steak the strain on minimal medium without any amino acids. The F' is maintained because it carries the proAB genes to complement the proAB deletion on the chromosome.
Another issue is that while you might need to add IPTG to really produce good color, in doing so you are doing to induce T7 polymerase expression from the DE3 prophage. So this may actually counter select against the colonies you want if you are cloning into a T7 expression system. So be cautious that you may be specifically selecting against the clones you want. That is probably why Promega says to not use it that way.
You would be better off to do the initial blue-white screening in a non-DE3 strain and then when you find the correct plasmid to retransform the DNA. However if you don't have any non-DE3 strains then you might try with just X-gal and no IPTG and you might still be able to see blue/white but more faintly.
  • asked a question related to Screening
Question
2 answers
Antibiotic resistance , enzyme production are types of screening method . Both have advantages and disadvantages so , in these two which method is more preferred to insert in vector and provides maximum results . Are there any considerations of these methods while performing gene cloning?
Relevant answer
Answer
Hi there,
Your question is a bit of unclear to me... When you mention enzyme production, do you mean the enzyme produced by the gene conferring resistance or do you mean the product of the gene of interest possibly cloned into the vector?
  • asked a question related to Screening
Question
3 answers
I am conducting a systematic review and after screening have come up with 9 included studies 6 of which are systematic reviews. Am I able to use these in my report and discussion? As the articles the reviews utilise / mention are outside of our date range?
Relevant answer
Answer
No,it is already shows polled effect
  • asked a question related to Screening
Question
3 answers
In the REDIAL project funded by Kidney research UK We are looking for a dynamic and talented early career researcher in the field of Computational Materials Science with a focus on Separation and Biomedical applications, who can effectively exploit Artificial Intelligence tools for the design of functional Materials and Sustainable Processes in the SusProM Group. https://www.suspromgroup.eng.ed.ac.uk/
The Opportunity:
  • To work in a highly interdisciplinary Research Team with Chemical Engineers, Bioengineers an Experts in Artificial Intelligence and undertake research on the computational simulation and screening of materials for the miniaturisation and circularisation of the hemodialysis process.
  • To exploit the research results to improve the life of kidney patients, in collaboration with Kidney Research UK and frequent contacts with patients, nephrologists and biologists during National events.
  • To deal mostly with computational work, but willing to carry out experimental validation in the lab if needed.
Your skills and attributes for success:
  • Computational material science skills (Molecular Simulations, Macroscopic models and Machine Learning)
  • Strong fundamental knowledge of materials for separation theory
  • Ability to apply fundamental skills to problem solving
  • Coding skills (Python preferred, Pytorch/tensorflow desirable)
  • Basic experience in the lab.
Relevant answer
Answer
when will you be submitting your PhD?
you can apply
  • asked a question related to Screening
Question
1 answer
I wanna use it in TSA medium to screen some characteristics of bacteria. I used 0.25g PbCl2 with 0.3ml HCl 12M, but this did not dissolve PbCl2
Relevant answer
Answer
as you see, it's insoluble
  • asked a question related to Screening
Question
3 answers
I need to use the AutoDock program, but I tried both versions 1.5.6 and 1.5.7. I had no problem loading, my only problem is that when I open the program, the loading remains around 9% in the window that opens. Then the window closes with the command page that opens. It will be more understandable when I add screen shots. I am using Win11 operating system, I have an HP brand laptop, I really can't figure out where the problem is. In the screenshot I attached, it stays as it is. The program closes directly.
Relevant answer
Answer
Sikao Guo I did everything, but it didn't work. I guess I need to find another computer or something. Thanks again for the advice
  • asked a question related to Screening
Question
3 answers
Metabolomics has emerged as an invaluable tool for prognostic and diagnostic purposes, last in the cascade of others OMICS -genomics, transcriptomics, and proteomics. Omics training usually covers experiment design, data generation, and collection, data preparation, data analysis, and the last but not the least - data interpretation.
At the end of this meticulous energy, time, and financial-consuming path, it might be totally none sense to fail to put your results into the broader biological context.
For those like me that have never been trained to interpret metabolomics data, how can we make sure to not miss important points? Is Basic knowledge in Biochemistry, Physiology, or physiopathology of the disease of your interest, enough to harness the full potential of metabolomics technologies for biomarker screening u.a?
I would like to discuss with experts out there, the most important assets for a right and successful data interpretation of metabolomics data.
Thank you for sharing your experience in the Metabolomics journey as well.
Relevant answer
Answer
Only advice I can give is to have a background in chemistry so you can identify what chemical groups make sense and to be able to investigate related chemical families or to predict parent compounds. For example there may very little on a glycoside but if you look up the parent compound as an alcohol or methoxy ether you can often find a trove of relevant literature. Read all the papers you can about the annotation for the compound as there can often be non-enzymatic routes to the formation of compounds (especially when ROS is involved). Look up other synonyms for the compound as these are not standardized, especially in older literature. Use KEGG to help visualize the pathways where possible and always doubt the automatic annotations. I have seen nature papers where their "marker" for a cancer type is actually a tropical plant alkaloid only produced in one family of trees from southeast Asia (the patient samples from that study were not even from that region of the world). Also if you think the metabolite is important you must always do an alternative assay to verify that it is the correct annotation.
  • asked a question related to Screening
Question
1 answer
I just established a cell line after long-term term culturing and would like to screen for contamination. I only have Hoechst 33342, and I would like to know whether it can be used for mycoplasma screening.
Relevant answer
Answer
Hello Xi Su
Yes, you may use Hoechst 33342 for mycoplasma screening.
Hoechst 33342 is a cell permeable fluorescent compound that is able to stain the DNA of eukaryotic as well as prokaryotic cells by binding with high affinity to the minor groove of AT-rich DNA sequences. Both Hoechst 33258 and Hoechst 33342 are very closely related bis-benzimides dyes, and are excited by ultraviolet light at around 350 nm, and both emit blue/cyan fluorescence light around an emission maximum at 461 nm. The key difference between them is that the additional ethyl group of Hoechst 33342 renders it more lipophilic, and thus more able to cross intact cell membranes. Hoechst 33258 is significantly less permeant.
You may use Hoechst 33342 for mycoplasma screening. Please refer to the link below. See page 28.
Hoechst 33342 is commonly used as a DNA binding dye to determine cell cycle status and apoptosis assays.
Best.
  • asked a question related to Screening
Question
2 answers
For example, if a biparental mapping population is screened for abiotic stress tolerance (drought/salt) with physiological parameters.
Relevant answer
Answer
Hi Nikolay, many thanks for your input. I highly appreciate your time and effort.
  • asked a question related to Screening
Question
2 answers
Hello everyone
I have done simulation of 100 ns by using gromacs.. and the following is hbond plot but its different i dont understand that every thing is fine but the data formate in .xvg file is different, its look like mixed up .. here i am attaching two screen shots but if you want to check the .xvg file then i will send you
Please someone help me i dont know the solution
Relevant answer
Answer
i have use this command but the same problem
gmx hbond -s md_0_1.tpr -f md_0_1_center.xtc -n index.ndx -num hbond.xvg
i dont know what is the main problem
can you please help me to sort it out.
  • asked a question related to Screening
Question
4 answers
Hello,
I'm looking to implement a fast method to screen anti-inflammatory products. Avoiding protein denaturation is linked to anti-inflammatory properties.
There is a nice number of papers describes a rapid and low cost screening method based on an incubation of the tests compound and a BSA solution (about 1 to 5% w:w) at higher temperature (usually 72°C) for a given time (between 5-20 min) buffered to ph6.4-6.6. Reading is done by spectrophotometry (usually 660nm). The method seems simple but when I try to implement, my reading is zero. I noticed that each laboratory introduces a slight change on the most cited protocol. I have introduced the major changes reported without any reading. Papers reporting the raw data indicates that after incubation the negative control (no test product of anti-inflammatory drug) DO is about 0.3-0.4.
Notice that all weightings, control and technicians have been investigated to try to find the root cause, unsuccessfully. Do anyone have any experience on this that can give me any advice?
Thanks
Relevant answer
Answer
Dear Adam,
Thanks for your comments but my DO reading is close to zero. No turbidity, no nothing a clear crystal solution.
Thanks again.
  • asked a question related to Screening
Question
4 answers
Are preoperative (3D printed) models, and drug testing/ screening models classified as medical devices? What category of devices do they fall under?
Relevant answer
Answer
  • asked a question related to Screening
Question
2 answers
Dear Colleagues,
I wish to perform a genotype-phenotype correlation study in a family with a known mutation in RPGR-ORF15.
However, the RPGR-ORF15 region is very tricky because it contains GC repeats and thus its not possible to amplify with standard PCR conditions.
Special protocols are needed for both PCR amplification as well as during Sanger sequencing.
Therefore, I would greatly appreciate if anyone could suggest me a commercial facility where I can send my samples for screening the specific mutation located in the RPGR-ORF15 region?
Number of samples to be screened = 05
Many thanks,
Atta
Relevant answer
Answer
There are several commercial facilities that offer specialized services for PCR amplification and Sanger sequencing of difficult regions like the RPGR-ORF15. Here are a few options:
  1. GeneWiz: They offer Sanger sequencing services for difficult templates, including those with GC-rich regions. They also have a team of experts who can assist with assay design and optimization.
  2. Eurofins: They offer custom PCR and sequencing services for challenging templates, and have experience with GC-rich regions. They also have a team of molecular biologists who can assist with assay design.
  3. GENEWAVE: They offer PCR amplification and Sanger sequencing services for difficult templates, and have experience with GC-rich regions. They also offer customized solutions for specific projects.
It is recommended to contact these companies and discuss the specifics of your project with them to determine which one is the best fit for your needs.
  • asked a question related to Screening
Question
1 answer
For example, when searching over the PubMed database, we get 125,000. But PubMed has some limitation that just allow us to screen until 1000 results. Do anyone come across this situation, and what you do to solve this issue, or anyway to report the results?
Relevant answer
Answer
PubMed allows you to export the first 10,000 results to a citation manager - click on the 'send to' button at the top of the search results. There are also other options to for export the results that may be more relevant to you.
However, you have to bear in mind the time it takes to screen the results. If you screen one result per minute, that is 420 results in a standard 7hr workday. Meaning to screen 125,000 would take 298 days. Obviously, this is not feasible.
Use more search terms, Boolean operators (AND, NOT, OR), and search filters to get your results to about 1000. That is reasonable for a systematic review.
  • asked a question related to Screening
Question
8 answers
Hi everyone, I wanted to know if there is a method that allows us to screen bioactive molecules with protective power against UV rays. For example, exposing a support containing the molecules to UV rays, and then we observe directly (visually) a character that allows us to select the protective molecules. Thank you in advance
Relevant answer
Answer
Can I directly evaluate the effect of the organic extract (ethyl acetate) for its protective power against UV rays?
  • asked a question related to Screening
Question
2 answers
Field screening of rice genotypes against brown plant hopper was done on the basis of hopper population/hill/week. The genotypes are to be categorized under different levels of resistance but there is slight confusion in choosing the standard scale for BPH evaluation under field conditions. Please help verify the two scales attached in JPG format or share any article or web link regarding my query.
Thank you
Relevant answer
Answer
Look this Rice-standart-evaluation-system from IRRI on 20 page. Hope it helps you.
The best regards Liane
  • asked a question related to Screening
Question
3 answers
I am working on the degradation capacity of naphthol by 6 bacteria isolated from wastewater which are : Pseudomonas aeruginosa , Pseudomonas Putida , pseudomonas fluorescens , Bacillus thuringiensis , Citrobacter freundii and Escherichia coli but I want to know which is the best composition of the minimum medium for the screening of these bacteria .
Thank you in advance.
Relevant answer
Answer
Yes , for utilization of naphthol as a carbon source .
  • asked a question related to Screening
Question
3 answers
Hi all,
I wonder whether there is a way to find the original natural product from the modified structure? It is very common to use natural product derivatives in HTS/HCS/in silicon screening to find more potent structures and/or SAR. Once, we have a candidate structure, is there any database where we can do search (based on structure similarity/substructure) and find the originated structure and the source (which plant, microorganism etc.)? Thanks
Best,
Burak
Relevant answer
Answer
  • asked a question related to Screening
Question
3 answers
Transformed bacterial screeening
Relevant answer
Answer
Thanks all!
  • asked a question related to Screening
Question
2 answers
Hi everyone,
I am currently trying to screen the behavioral effects of the 6-OHDA unilateral injection in the striatum of Wistar male rats to confirm a Parkinson's animal model by apomorphine-induced turning behavior test (or rotameter test).
Although the dose of apomorphine is prepared according to the articles and is injected intraperitoneally to the rats, but instead of turning against the injection site of the neurotoxin, the rats become extremely relaxed and even fall asleep, and it is not possible for me to check the behavior.
I have request from dear students, professors and scientists that help me to find out what the main problem is and share the tips of rotameter test with me.
Please feel free to have contact with me.
Thank you for reading and helping!
Relevant answer
Answer
Please find the detailed protocol attached.
Thanks
Samir
  • asked a question related to Screening
Question
4 answers
I have National Cancer Institute screening results of my compounds. Upon submission, I am asked by the reviewers to provide standard deviations, what kind of statistical analysis was performed, and its significance. I have scourged the NCI methodology section and many publications throughout the years and couldn't find anyone who met these criteria.
Relevant answer
Answer
Emmanuel Curis The main problem is that NCI doesn't provide individual data of each experiment. Instead, they provide you with the mean. for every cell line.
  • asked a question related to Screening
Question
3 answers
I used 0.5% Aq. AcOH solution to dissolve chitosan and derivative to evaluate their antimicrobial activity and performed anti-bacterial activity and antifungal activity using the broth dilution technique in 96-well micro-trays (NCCLS, 1993) and the antifungal screening method (NCCLS M27-A2 protocol, respectively. The cytotoxicity tests of prepared chitosan derivatives were assessed by MTT assay.
Now reviewer have following comment.
kindly help me in replying the comments of reviewers
comment of reviewer: if the derivates are still not soluble in water how are they be used in the kind of treatment proposed? What it's the implication of using acidic media in antimicrobial or cytotoxic treatment ?
Relevant answer
Answer
The reviewer is apparently concerned that the solution is not useful for clinical application due to the acetic acid - that one can not for example inject acetic acid internally. You need to defend the safe use of acetic acid internally AND that chitosan remains solubilized when delivered to the tumor in the body.
  • asked a question related to Screening
Question
8 answers
Hi all..
I am doing the in silico and in vitro anti-tuberculosis screening. Any one engaged in finding anti-tuberculosis compounds or related screening work. Hope someone engaged in the area can help me.
Thankyou in advance.
Shefin
Relevant answer
Answer
Dear Dr Kholis,
Yes it's possible
  • asked a question related to Screening
Question
9 answers
I have a bit of a semantic question in relation to a paper I am writing.
Recently, I had a discussion with my supervisor on Type-II errors. In my recent statistic course, the type-II errror was defined as falsely not rejecting H0. A lack of power is often described as a cause of a type II error. As such, I was under the assumption that a type-II error is mostly used in the context of statistical tests.
However, my supervisor explained that "type-II error" could just as well be used describe any false negative result, also when it relates to methodological problems e.g. using the wrong measurement instrument for your aims and falsely not finding any effect.
I cannot find anything on pubmed on this matter. I screened some papers mentioning the Type-II error but all used it in a statistical context, not more general.
As such, my question is whether 'type-II error' only relates to a statistical problem or also to a broader definition of false negative outomes?
Thank you.
Relevant answer
Answer
A Type II error is a decision error made about the data. Additionally, there must be a hypothesis of some kind present. A measure, instrument, or procedure does not contain a hypothesis.
Perhaps your advisor is getting at something like this: If a study has a flawed methodology, this will affect the data, which could result in a Type II error (miss). So, one's methodology could indirectly lead to a Type II error, but the error itself is about the data - not the measure or procedure used to collect the data.
  • asked a question related to Screening
Question
3 answers
any technical input for PCR confirmation
Relevant answer
Answer
Hpt confers hygromycin resistance so can be used as a marker gene. Use hygromycin selection and all surviving plants should be what you want. If you really need to PCR your plasmid genes as a positive control you can just use the plasmid sequence to design primers and then BLAST them against the genome of your plant.
  • asked a question related to Screening
Question
3 answers
I have read various articles in which plastic degraders are screened using PEG-containing MSM media. But which PEG is used is not mentioned. So, I used PEG-6000 as the sole Carbon source to isolate the plastic degraders.
I want to get suggestions about the best solid medium for plastic degraders.
Relevant answer
Answer
Kindly review it will help you out.
  • asked a question related to Screening
Question
3 answers
I need to screen my plant extract for all the compounds present in it. So i want to know which technique (without using standards) will give me the results
Relevant answer
Answer
At first, the objectives of the experiment, the type of secondary metabolite, the appropriate plant organ and the sample preparation processes should be considered and determined. Then, according to the available literature reviews, the effective isolation and identification techniques should be used to achieve the desired result.
  • asked a question related to Screening
Question
1 answer
I submitted a paper in the field of neutron/ gamma pulse shape discrimination and received a reviewer's comment requesting the following: "A scatter diagram and FoM diagram of screening factors shall be supplemented appropriately."
Hoping anyone can tell me what the reviewer means by screening factors. Thanks.
Relevant answer
Answer
Factor screening means searching for the most important factors (or inputs) among the many factors that may be varied in an experiment with a real or a simulated system.
  • asked a question related to Screening
Question
1 answer
I would like to create peptidomemetics based on a certain known peptide in silico.
For this I am asking if there can be any good references on this topic. (in silico specifically)
What I Want to do is; to create a small library of these peptidomemetics, then to screen their ability to dock a certain active site, then to run a molecular dynamics simulation to check the stability of the complex and the affinity to each of them.
Potential inquiries are;
Which software to use for building?
Which software for docking?
Which software to get parameters for these peptidomemetic to run the Mds? Or is there a preferred forcefield for these compounds?
Or
Should I deal with them in the same way as small molecules (this can be an answer that reliefs me at the end)
Relevant answer
Answer
The Molecular Modeling Tool Kit (MMTK) is a user-friendly software package for building and simulating peptidomimetics. It includes tools for building and manipulating peptide structures, and it can be used to generate a variety of peptidomimetic structures, such as small molecules and peptidomimetics. The PyMOL Molecular Graphics System is a powerful open source software package for creating peptidomimetics. It includes tools for building and manipulating peptide structures as well as visualizing them. For docking, the AutoDock Vina software is a widely used open source program for protein-ligand docking. It is a powerful tool for predicting the binding affinity of peptidomimetics to the target protein.
  • asked a question related to Screening
Question
4 answers
Is there any maximum number for studies that can be included in scoping review?
This is Homa Arshadi, Ph.D. Candidate of medical library and information sciences. I need some help with the following question. Could you please kindly advise me.
I'm doing a scoping review on text mining topic. The number of records identified after searching databases are about 10,000. After screening of 60 percent of these records, about 500 of papers are eligible, which must be read by full text. Is it reasonable to perform such review? What is the maximum number of studies to be included in a scoping review?
Many thanks in advance!
Kind Regards,
Homa
Relevant answer
Answer
Hi Homa, I don’t believe there is a recommended maximum of studies to be included in a scoping review (not that ive come across any way). You seem to be getting a large number of results so it could be worth revising your research question with you supervisor and/or search strategy with a librarian to narrow your focus (if you haven’t already). Id recommend Covidencr software. I found it useful for managing the data.
  • asked a question related to Screening
Question
1 answer
Dear colleague,
I am looking for advice regarding my research project. I collect number of patients with diagnosis and number of patinet with those diagnosis who were screened for sertain conditions each year 2019/2020/2021 (for instance blood glucose among diabetes patients). Therefore, those two numbers provide a rate for specific year. My idea is to compare those rates between years. However, I am not sure what kind of test to use? Fluctuation between years in denominator were not so big beyond natural flow. But, I also think that someone who skipp a screening one year has to intention to skipp it again.
Any other idea and solutions are welcome
Thnaks for your replays.
Best,
Aleksandar
Relevant answer
Answer
yes
  • asked a question related to Screening
Question
6 answers
Hi, I need to check microbial growth on wastes rich in proteins that tends to ferment pretty quickly. To get an idea of what and how much it's growing, I thought about using Plate Count agar, YS or YM for screening for yeasts, maybe Violet Red Bile for gram negative. What can I use to check protease activity? Since it's a mixed colture, I cannot use super selective media.
Could this course of action work for a totally uknown mixed colture? The goal is to identify the microrganisms responsible of spoilage and fermentation.
Thanks in advance for the help.
Relevant answer
Answer
Screen? Screen for what attribute?
  • asked a question related to Screening
Question
2 answers
In some papers I find out they are using both the cell lines (STF and STF3A cells) for screening of Wnt inhibitors.
Is it okay to use only STF3A cells for screening of Wnt inhibitors?
Relevant answer
Answer
Thank you so much for all the information about the STF3a cell line. Amos Bairoch
  • asked a question related to Screening
Question
2 answers
I am used to pre-incubate the test compounds with enzyme for durations ranging from 15 min to 45 min before adding the substrate and initiating the reactions. However, in process of designing a high-throughput method, that seems to be a lagging factor.
Hence the question.
Relevant answer
Answer
I agree generally with Nick Gee and would like to make a few more points.
Typically when one is screening a generic compound library for noncovalent inhibitors, the potency of the inhibitors is expected to be pretty weak. Such weak inhibitors (assuming they are specific inhibitors, see below) are expected to be in rapid equilibrium with the target enzyme, so there is no need to preincubate. An exception would be if you are screening a set of compounds that are expected to contain slow-binding inhibitors, which might be the case if the compounds in the screen are related to known slow-binding inhibitors of the enzyme. (A second exception would be if you are screening a set of compounds that are supposed to be covalent inhibitors, since their potency is time-dependent, as Nick Gee said.)
Time-dependence of inhibition is one typical characteristic of non-specific inhibitors such as aggregators or reactive contaminants of compound samples. Therefore, a test for such undesirable modes of inhibition is to compare the potency of the inhibitor sample at different times of the reaction, or with and without preincubation followed by a short reaction time. This test would, of course, not be done during the initial screen but could constitute part of the hit follow-up.
  • asked a question related to Screening
Question
3 answers
I want to transffer pKD46 into L. lactis NZ9000 by electroporation and screen cells through carbenicillin, but failed. I can transffer pNZ8148 and pll29 into NZ9000, but never pKD46, even with 5 μg/mL carbenicillin.
Relevant answer
Answer
Ok, I stand corrected, I had not previously seen any papers showing pSC101 origin functioned in G+.
  • asked a question related to Screening
Question
2 answers
On screening If MNS blood grouping is incompatible, can the blood go forward for blood transfusion?
Relevant answer
Answer
It depends on the immunological statute of the recipient.
1. If the recipient is immunized against MNS antigens (mainly MNS3 and MNS4), anti-MNS3 and anti-MNS4 are clinically significant, they cause post-transfusion haemolytic reactions and haemolytic disease of the fetus/new born. So, in this situation the RBC’s units selected must be negative for these antigens and must show negative reaction when tested with recipient serum
2. If the recipient is not immunized, it's not necessary to select compatible RBC’s units for MNS antigens
3. Except for sickle anaemia patients which are at a high risk of immunization. It’s really recommended to select compatible RBC’s units for the RH, KEL, Duffy, KIDD and MNS antigens for these patients even if they are not immunized.
  • asked a question related to Screening
Question
18 answers
Most experts agree that adults should limit screen time to less than two hours per day outside of work-related activities. Excessive screen time not only produces its own negative effects like eye strain and headaches, but it also steals time from more healthful pursuits like forging real-world connections and exercise.
I usually spend 3-4 hours on screen besides work related activities and I am trying to reduce it.
Relevant answer
Answer
As a lecturer, a researcher, and most importantly a father for 5 kids, I have seen over the years that the students, in general, haven’t real knowledge. From my personal perspective, the rationale behind this relates to the following facts:
  • Most of their time is concentrating on social media, games, and music more than learning. In turn, they are weak in the research process.
  • They think that their educators or instructors are not too smart to catch their plagiarize in the exams or assignments.
  • Most of them are suffering from financial problems. Some work more than 12 hours per day. As a consequence, they haven’t time to sleep or read.
  • The students haven't enough self-confidence. They believe that following the others is more valuable more than working on building themselves.
  • Furthermore, they have a lack of ideas about the consequences of their decisions.
  • Most of them haven't the ability to write a full completed paragraph. They usually use the copy-paste process for their assignments and projects.
  • I am so sorry to say that most of them have an internal belief of why I should read and study if I can get high marks by cheating.
  • asked a question related to Screening
Question
3 answers
Dear All,
Solid phase extraction (SPE) commonly forms part of LCMS, GCMS analytical chemistry or in vitro bioassay testing workflows to screen for organic environmental chemicals. Once samples have been passed through columns (E.g. HLB, C18, C8 etc.), the organic compounds are eluted using a solvent, dried and re-constituted in the solvent of choice.
The drying step is typically performed using nitrogen gas. I have seen protocols describing the drying of SPE extracts under a stream of air (such as in an extraction hood) instead of nitrogen.
Is there a particular reason why N2 is used for drying? Such as chemicals becoming oxidized? Could simple drying using air compromise the integrity of a sample?
Relevant answer
Answer
Most folks that I have seen who use N2, either have a sitewide supply which is delivered by tanker truck, or, in smaller facilities have a N2 generator.
A compressor would need a receiver tank to give capacity, and then the oil / water clean up system to remove compressor oil and moisture from the system. I'm sure some kind of filters could be added to remove any other impurities. As ever, the challenge with any filter is how one knows when the filter is spent, and should be changed.
I am a bit out of date since I last benchmarked costs of the above two solutions, and the price of everything has gone crazy these last few years, but prior to the new normal a N2 generator and a complete compressor system with clean up came out about the same kind of investment. That could have changed.
It's a long time since I visited your faculty, there was a vacuum concentrator within the plant metabolomics group, that may be a potential alternative. I remember that the researcher leading the group had done some clever GM work to double the sucrose output of sugar cane.
[For full disclosure, I work for the company that makes that vacuum equipment.]
  • asked a question related to Screening
Question
1 answer
50+ genotypes, 2 Treatments, 26 parameters are recorded during screening data. so what is your recommendation about graph making software and graphs name. Your answers will be highly acknowledge.
Relevant answer
Answer
"spider chart" ?! might be worth trying
  • asked a question related to Screening
Question
2 answers
this is regarding nitrate determination by 4500-NO3 B. Ultraviolet Spectrophotometric Screening Method. when the organic matter content is high, can we use an Allum solution to precipitate the organic matter (we have a wastewater sample which contaminated with tannin. this is from coir industry) once we add allum, colour and turbidity can be removed. so can we use the above method to determine the nitrate content?
Relevant answer
Answer
Multiple wavelength measurements may also help
  • asked a question related to Screening
Question
4 answers
We performed a TMS-related meta-analysis, and most of the TMS studies were within-subject designs. The reviewer said that "the conventional method for estimating effect size is not applicable to the within-subject design. However, it seems that the authors simply ignored this methodological issue and did not utilize other measures to calibrate the values they derived." We have no idea why within-subject effect sizes were un-applicable for meta-analysis, because numerous previous studies did so. And we are unaware of "other measures" to calibrate the within-subject effect sizes. To note, these studies screened for meta-analysis were finely designed, not the ones taking pre-and post-tests without a control condition for observing the intervention effects.
Relevant answer
Answer
The reviewer doesn't know what he is talking about. If you get the opportunity to respond to this reviewer (meaning the manuscript did not get outright rejected), point out three or so published systematic reviews/meta-analyses that included studies using a within-subjects research design. Though it is probably better if you include systematic review/meta-analysis studies from your field
  • asked a question related to Screening
Question
5 answers
I am going to test the antimicrobial activity of extracts against different bacteria. I need to test a few thousand compounds so I am going to do this in a 384-well plate. Does anyone have a protocol for the screening in a 96-well or 384-well plate? Thank you
Relevant answer
Answer
Without knowing your setup, i figure in the 384 well you will only see growth or no growth, so you only have very limited information and might have false negative events. You could in fact use it as a pre-screen, but you might falsly exclude candidates. Kirby Bauer ist very robust and straightforward.
Sure you can do it in 384, but I'd prefer to see the zone of inhibition.
  • asked a question related to Screening
Question
2 answers
Hi all,
I am having a problem with my PCR products, made from genomic DNA extracted from samples of Euphausia superba, basically Krill from Antarctica.
PCR products are for a 16s sequencing of the hypervariable region V3-V4, 500 bp construct.
I run the gDNA to understand if the problem is in the extraction part (because these are samples extracted from another lab) and the run went well, then I run the normal PCR products and all the signal is in the wells.
Then, I cleaned up gDNA and PCR products with magnetic beads, and after the PCR cycle to amplify those regions of the newly cleaned gDNA I had the same problem, with both samples (cleaned up amplified gDNA and cleaned up old PCR products) stuck in the well.
THEN, I thought that maybe the problem might be caused by DNA binding protein or by some ions that "screen" the charges and there is no migration (because this creature lives in super cold regions and might have some sort of molecular mechanism that protects against freezing), so I used isopropanol + ammonium acetate to try to extract DNA from them, but even with this step, I had the same result.
Before I try with SDS to achieve the extraction ( or before I drink it to end my life), does someone have the same problem?
I uploaded one of the gels (the one with PCR products that weren't cleaned up).
The first 4 columns are the same protocol but with a different creature (you can see the pcr products near the marker, and the other ones are all PCR from krill). Those bands below are clearly primer dimers.
Relevant answer
Answer
Ooof, that is a very messy gel. First, you should wash your gel rig: casting tray, combs, box, etc. Use a mild detergent & then rinse well in distilled water. Dirty gel combs can cause this issue due to high residual salt. And make new electrophoresis buffer.
It does look like you are getting amplification, those bands are bright. My guess is it's just an issue with your electrophoresis equipment. If the DNA had that high of a salt/mineral content, you probably wouldn't see amplification. You can also try diluting the DNA (e.g. 1:10, 1:50, 1:100). That can reduce the concentration of PCR inhibitors & still have more than enough template.
Good luck!
  • asked a question related to Screening
Question
12 answers
My source laser is a 20mW 1310nm DFB laser diode pigtailed into single-mode fiber.
The laser light then passes into an inline polarizer with single-mode fiber input/output, then into a 1x2 coupler (all inputs/outputs use PM (polarization maintaining) Panda single mode fiber, except for the fiber from the laser source into the initial polarizer). All fibers are terminated with and connected using SC/APC connectors. See the attached diagram of my setup.
The laser light source appears to have a coherence length of around 9km at 1310nm (see attached calculation worksheet) so it should be possible to observe interference fringes with my setup.
The two output channels from the 1x2 coupler are then passed into a non-polarizing beam splitter (NPBS) cube (50:50 reflection/transmission) and the combined output beam is projected onto a cardboard screen. The image of the NIR light on the screen is observed using a Contour-IR digital camera capable of seeing 1310nm light, and observed on a PC using the software supplied with the camera. In order to capture enough light to see a clear image, the settings of the software controlling the camera need to have sufficient Gain and Exposure (as well as Brightness and Contrast). This causes the frame rate of the video imaging to slow to several second per image frame.
All optical equipment is designed to operate with 1310nm light and the NPBS cube and screen are housed in a closed box with a NIR camera (capable of seeing 1310nm light) aiming at the screen with the combined output light from the NPBS cube.
I have tested (using a polarizing filter) that each of the two beams coming from the 1x2 coupler and into the NPBS cube are horizontally polarized (as is the combined output beam from the NPBS cube), yet I don't see any signs of an interference pattern (fringes) on the screen, no matter what I do.
I have tried adding a divergent lens on the output of the NPBS cube to spread out the beam in case the fringes were too small.
I have a stepper motor control on one of the fiber beam inputs to the NPBS cube such that the horizontal alignment with the other fiber beam can be adjusted in small steps, yet no matter what alignment I set there is never any sign of an interference pattern (fringes) in the observed image.
All I see is a fuzzy blob of light for the beam emerging from the NPBS cube on the screen (see attached screenshot) - not even a hint of an interference pattern...
What am I doing wrong? How critical is the alignment of the two input beams to the NPBS cube? What else could be wrong?
Relevant answer
Answer
Gerhard Martens Thanks! I guess that is my problem solved.... Thanks for your input and suggestions.... :-D
  • asked a question related to Screening
Question
1 answer
I prepped a cDNA library from ovarian cancer cell line RNA (all RIN scores were 9+ on TapeStation 4200) using a KAPA HyperPrep mRNA kit and UDI adapters for Illumina sequencing. When we ran the TapeStation (D1000 HS screen tapes) on the prepped libraries, we saw extra peaks around 230-250bp. On some samples it was a more pronounced peak, but others it was more of a shoulder. We are baffled on what this could be from. We did a QC sequencing run on an illumina nextseq P2 100 cycle and are wondering if our inner distance plot could look like this due to the smaller fragments we see on the tape station? I've had some people suggest the extra peak on the tapestation a bubble peak from over amplification of the library, but bubble peaks would appear larger, not smaller. Our anticipated library size was 200-300bp. For most samples the average size was 350bp, so including the adapter sequences this seems right. We just have no idea what the smaller peak would be that appear in nearly every sample. I've included images of a couple electropherograms and gel images from the tapestation and the inner distance plot. You can see these smaller extra peaks appear as bands on the gel images and how they slightly vary in size from sample to sample.
Relevant answer
Answer
Recently, I tried to understand what conditions would lead to short fragment carryover among NGS libraries that are not detected by fragment analysis but observed during sequencing. Heteroduplexing is possible when PCR conditions are not optimal, which could result from an imbalance between primer and template early or late in its progresses. The article below describes the effect of heyeroduplex molecules on fragment size (as determined by electrophoresis). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC113844/#:~:text=To%20recondition%20the%20PCR%20product,through%20a%201%25%20agarose%20gel.
In your case, however, the sequencing result seems to march the tapestation size profile. This leads be to believe the presence of short (240bp) is real. Thus my attention is drawn to the ligation step, which leads to high incidence of short fragments is setup under suboptimal conditions. Placing reaction tubes on chiller blocks lead to higher incidence of adapter-adapter formation. Likewise, pipette mixing the ligation master mix with the cDNA before addition of the adapte lead to a similar result. Pipetting along the side of the reaction vessel to add the components before a final pipette mix to form a homogenous solution is advisable as these ligation mixtures are fast acting.
If over-amplification is a concern, determining cycle number by qPCR might be worth considering. Else, reconditioning PCR would relieve Heteroduplexing issues (Link above).